a green dill
Release time:
2020-08-14
一枝绿萝
我有一个杯子，粉红色杯身，黑色的底座，有一种稳重踏实的感觉，像是一个优雅的花瓶。一天同事送我一枝绿萝，从此，粉红色杯子就成了它的家，绿色的新芽从杯口舒展着，让人赏心悦目。
绿萝的叶子绿油油的，像镀了一层光一样生机勃勃。我把它放在办公桌上，一天拿出来看个无数次，期待它早点长根。为此，我悉心照顾，每三天换一次水，每天带它到窗户边晒一会儿太阳。夏天的天气热得要命，但隔着窗户在26℃的空调房内迎着外面灿烂的阳光，对植物来说应该是最舒服的了。绿萝果然生命力极强，即使没有根，它也一直绿意盎然。
做什么事情都不是随随便便就能随心顺意的。两周了，绿萝依然没有长根的迹象。插在水里的那一截越来越黄，看起来情况不大妙！我赶紧上网查原因，用排除法一一进行梳理。以我浅薄的养花经验分析，大概有两个原因。一是水的问题，网上说自来水不可直接用来水培植物，原因是自来水中所含的漂白粉和氯气对植物有损伤；二是温度的原因，上班时间办公室26℃，下班后关了空调，温度很快上升至38℃以上，温差太大导致不能正常生长。分析出原因后，水的问题好解决，自来水提前接来放两三天就好，温度呢？我左思右想。既然无法保证下班之后的温度，只好在上班时间也不再维持26℃。最后，终于找到一个没有空调而又相对阴凉的水池边，我强忍对绿萝的喜爱，把它放在平时看不到的地方，也防着自己每天把它拿出来看个无数次。
时隔一周，绿萝果然给了我一个惊喜，嫩嫩的芽节上长出了一小点白白的根，好像在告诉我：我活着呢，别担心。有回应的感觉真好。我不敢贸然带它回办公桌，继续把它留在原地。
又过了一周再去看，原来的根长长了，旁边还新发了一根。太好了，我终于把它养活了，妥妥地活了！我终于可以放心大胆地带它回到办公桌上，一方面实在很想见证它的成长，另一方面，酷热的天气终于渐渐凉了。
现在，我的绿萝长得很好，生机勃勃。养绿萝的过程虽然辛苦，但是它却给我一种积极的能量，以一种悄无声息的方式打动着我。我善待它，照顾它，也从它那里得到幸福的滋润，温暖善意的回报。
植物是干净的，是生长的，是顽强的，也是有意念的。（张阿利）
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page